Standout Papers

Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes 2008 2026 2014 2020 834
  1. Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes (2012)
    Hans‐Henrik Parving, Barry M. Brenner et al. New England Journal of Medicine
  2. Aliskiren Combined with Losartan in Type 2 Diabetes and Nephropathy (2008)
    Hans‐Henrik Parving, Frederik Persson et al. New England Journal of Medicine
  3. Combination therapy for kidney disease in people with diabetes mellitus (2024)
    Daniël H. van Raalte, Petter Bjornstad et al. Nature Reviews Nephrology

Immediate Impact

2 by Nobel laureates 7 from Science/Nature 106 standout
Sub-graph 1 of 16

Citing Papers

Mass-spectrometry-based proteomics: from single cells to clinical applications
2025 StandoutNature
Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial
2024 Standout
50 intermediate papers

Works of Frederik Persson being referenced

Combination therapy for kidney disease in people with diabetes mellitus
2024 Standout
Efficacy of Dapagliflozin by Baseline Diabetes Medications: A Prespecified Analysis From the DAPA-CKD Study
2023
and 22 more

Author Peers

Author Last Decade Papers Cites
Frederik Persson 3217 1866 2281 180 6.0k
James W. Scholey 2191 2260 2919 135 8.1k
Richard J. MacIsaac 2648 2399 1115 224 6.6k
R. J. Jarrett 4379 1703 2255 93 7.8k
Kevin D. Burns 1648 1298 2331 156 5.9k
Roberto Trevisan 2584 1726 1258 125 5.2k
Anna Solini 2556 1087 1415 228 7.1k
Susan B. Gurley 1694 909 2154 84 5.1k
Michael W. Steffes 2504 2378 1081 142 8.6k
A Mimran 1535 1471 3017 235 5.4k
T. Deckert 5227 3667 2644 176 10.3k

All Works

Loading papers...

Rankless by CCL
2026